UNASSIGNED: Patients diagnosed with HER2-negative BC ( N = 999) at our institution between January 2011 and December 2015 formed our study population. Clinicopathological characteristics, association between estrogen receptor (ER) expression and HER2-low, and evolution of HER2 immunohistochemical (IHC) score were assessed. Kaplan-Meier method and log-rank test were used to compare the long-term survival outcomes (5-year follow-up) between the HER2-IHC0 and HER2-low groups.
UNASSIGNED: HER2-low BC group tended to demonstrate high expression of ER and more progesterone receptor (PgR) positivity than HER2-IHC0 BC group ( P < 0.001). The rate of HER2-low status increased with increasing ER expression levels (Mantel-Haenszel χ 2 test, P < 0.001, Pearson\'s R = 0.159, P < 0.001). Survival analysis revealed a significantly longer overall survival (OS) in HER2-low BC group than in HER2-IHC0 group ( P = 0.007) in the whole cohort and the hormone receptor (HR)-negative group. There were no significant differences between the two groups in terms of disease-free survival (DFS). The discordance rate of HER2 IHC scores between primary and metastatic sites was 36.84%.
UNASSIGNED: HER2-low BC may not be regarded as a unique BC group in this population-based study due to similar clinicopathological features and prognostic roles.
■2011年1月至2015年12月在我们机构诊断为HER2阴性BC(N=999)的患者构成了我们的研究人群。临床病理特征,雌激素受体(ER)表达与低HER2之间的关联,评估HER2免疫组织化学(IHC)评分的演变。使用Kaplan-Meier方法和log-rank检验比较HER2-IHC0组和HER2低组之间的长期生存结果(5年随访)。
■HER2低BC组比HER2-IHC0BC组倾向于显示ER的高表达和更多的孕激素受体(PgR)阳性(P<0.001)。HER2低状态的比率随着ER表达水平的增加而增加(Mantel-Haenszelχ2检验,P<0.001,Pearson的R=0.159,P<0.001)。生存分析显示,在整个队列和激素受体(HR)阴性组中,HER2低BC组的总生存期(OS)明显长于HER2-IHC0组(P=0.007)。两组在无病生存期(DFS)方面没有显着差异。原发灶和转移灶HER2IHC评分不一致率为36.84%。
■在这项基于人群的研究中,由于相似的临床病理特征和预后作用,HER2低BC可能不被视为独特的BC组。